PharmGen Science, Inc. (004720.KS)
KRW 4035.0
(0.62%)
KRW 4035.0
(0.62%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 107.7 Billion KRW | -2.33% |
| 2022 | 110.27 Billion KRW | 18.08% |
| 2021 | 93.39 Billion KRW | 79.69% |
| 2020 | 51.97 Billion KRW | 18.69% |
| 2019 | 43.78 Billion KRW | 5.91% |
| 2018 | 41.34 Billion KRW | 137.26% |
| 2017 | 17.42 Billion KRW | -37.52% |
| 2016 | 27.89 Billion KRW | 56.78% |
| 2015 | 17.79 Billion KRW | -18.86% |
| 2014 | 21.92 Billion KRW | 41.51% |
| 2013 | 15.49 Billion KRW | -7.27% |
| 2012 | 16.7 Billion KRW | -30.76% |
| 2011 | 24.13 Billion KRW | -17.06% |
| 2010 | 29.09 Billion KRW | -8.71% |
| 2009 | 31.87 Billion KRW | -40.8% |
| 2008 | 53.84 Billion KRW | 28.18% |
| 2007 | 42 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 110.11 Billion KRW | 1.02% |
| 2024 Q1 | 109 Billion KRW | 1.21% |
| 2023 Q2 | 122.53 Billion KRW | 9.62% |
| 2023 Q3 | 121.99 Billion KRW | -0.44% |
| 2023 FY | 107.7 Billion KRW | -2.33% |
| 2023 Q1 | 111.78 Billion KRW | 1.36% |
| 2023 Q4 | 107.7 Billion KRW | -11.71% |
| 2022 Q3 | 113.69 Billion KRW | 2.35% |
| 2022 Q4 | 110.27 Billion KRW | -3.01% |
| 2022 FY | 110.27 Billion KRW | 18.08% |
| 2022 Q2 | 111.07 Billion KRW | -14.86% |
| 2022 Q1 | 130.47 Billion KRW | 39.7% |
| 2021 Q2 | 92.57 Billion KRW | 58.53% |
| 2021 Q4 | 93.39 Billion KRW | -2.4% |
| 2021 FY | 93.39 Billion KRW | 79.69% |
| 2021 Q3 | 95.68 Billion KRW | 3.37% |
| 2021 Q1 | 58.39 Billion KRW | 12.35% |
| 2020 FY | 51.97 Billion KRW | 18.69% |
| 2020 Q2 | 34.18 Billion KRW | -5.31% |
| 2020 Q1 | 36.09 Billion KRW | -17.56% |
| 2020 Q4 | 51.97 Billion KRW | 81.71% |
| 2020 Q3 | 28.6 Billion KRW | -16.32% |
| 2019 Q2 | 43.01 Billion KRW | 0.77% |
| 2019 FY | 43.78 Billion KRW | 5.91% |
| 2019 Q4 | 43.78 Billion KRW | 4.49% |
| 2019 Q3 | 41.9 Billion KRW | -2.58% |
| 2019 Q1 | 42.68 Billion KRW | 3.25% |
| 2018 Q3 | 17.92 Billion KRW | -8.97% |
| 2018 FY | 41.34 Billion KRW | 137.26% |
| 2018 Q1 | 19.57 Billion KRW | 12.36% |
| 2018 Q2 | 19.68 Billion KRW | 0.56% |
| 2018 Q4 | 41.34 Billion KRW | 130.7% |
| 2017 Q4 | 17.42 Billion KRW | 4.04% |
| 2017 FY | 17.42 Billion KRW | -37.52% |
| 2017 Q1 | 18.79 Billion KRW | -32.63% |
| 2017 Q2 | 15.16 Billion KRW | -19.3% |
| 2017 Q3 | 16.75 Billion KRW | 10.46% |
| 2016 Q2 | 30.08 Billion KRW | 0.83% |
| 2016 FY | 27.89 Billion KRW | 56.78% |
| 2016 Q3 | 30.54 Billion KRW | 1.53% |
| 2016 Q1 | 29.83 Billion KRW | 67.68% |
| 2016 Q4 | 27.89 Billion KRW | -8.67% |
| 2015 Q4 | 17.79 Billion KRW | 14.23% |
| 2015 Q3 | 15.57 Billion KRW | -3.83% |
| 2015 FY | 17.79 Billion KRW | -18.86% |
| 2015 Q1 | 22.3 Billion KRW | 1.73% |
| 2015 Q2 | 16.19 Billion KRW | -27.4% |
| 2014 Q3 | 19.84 Billion KRW | -2.24% |
| 2014 Q4 | 21.92 Billion KRW | 10.52% |
| 2014 Q2 | 20.29 Billion KRW | 40.48% |
| 2014 Q1 | 14.44 Billion KRW | -6.77% |
| 2014 FY | 21.92 Billion KRW | 41.51% |
| 2013 Q3 | 15.48 Billion KRW | 2.31% |
| 2013 FY | 15.49 Billion KRW | -7.27% |
| 2013 Q1 | 14.35 Billion KRW | -14.07% |
| 2013 Q2 | 15.14 Billion KRW | 5.44% |
| 2013 Q4 | 15.49 Billion KRW | 0.03% |
| 2012 Q2 | 20.43 Billion KRW | -6.63% |
| 2012 Q1 | 21.88 Billion KRW | -9.3% |
| 2012 FY | 16.7 Billion KRW | -30.76% |
| 2012 Q4 | 16.7 Billion KRW | -9.09% |
| 2012 Q3 | 18.37 Billion KRW | -10.07% |
| 2011 FY | 24.13 Billion KRW | -17.06% |
| 2011 Q2 | 29.6 Billion KRW | -2.16% |
| 2011 Q1 | 30.25 Billion KRW | 3.99% |
| 2011 Q4 | 24.13 Billion KRW | -7.7% |
| 2011 Q3 | 26.14 Billion KRW | -11.68% |
| 2010 FY | 29.09 Billion KRW | -8.71% |
| 2010 Q1 | 32.56 Billion KRW | 2.16% |
| 2010 Q2 | 32.81 Billion KRW | 0.78% |
| 2010 Q3 | 31.03 Billion KRW | -5.42% |
| 2010 Q4 | 29.09 Billion KRW | -6.25% |
| 2009 Q2 | 53.99 Billion KRW | -1.19% |
| 2009 Q1 | 54.64 Billion KRW | 1.5% |
| 2009 Q4 | 31.87 Billion KRW | -33.74% |
| 2009 Q3 | 48.09 Billion KRW | -10.92% |
| 2009 FY | 31.87 Billion KRW | -40.8% |
| 2008 Q3 | 50.96 Billion KRW | 8.49% |
| 2008 Q2 | 46.97 Billion KRW | 0.0% |
| 2008 FY | 53.84 Billion KRW | 28.18% |
| 2008 Q4 | 53.84 Billion KRW | 5.64% |
| 2008 Q1 | 46.97 Billion KRW | 11.83% |
| 2007 Q2 | 51.22 Billion KRW | 10.92% |
| 2007 Q4 | 42 Billion KRW | 10.09% |
| 2007 Q3 | 38.15 Billion KRW | -25.51% |
| 2007 FY | 42 Billion KRW | 0.0% |
| 2007 Q1 | 46.18 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Daewoong Co., Ltd. | 922.47 Billion KRW | 88.324% |
| Wooridul Huebrain Limited | 17.6 Billion KRW | -511.954% |